Featured Research

from universities, journals, and other organizations

New Results Help Predict Treatment Response In Colorectal Cancer

Date:
September 18, 2008
Source:
European Society for Medical Oncology
Summary:
Gene marker indicates doubling of survival time in advanced colorectal cancer treated with cetuximab. A study shows value of circulating tumor cells in patients on targeted therapy.

Genetic testing can identify a group of patients with advanced colorectal cancer who are likely to survive on average twice as long if treated with the drug cetuximab, late breaking results show.

Related Articles


At the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm, Dr. Christos Karapetis from Flinders University in Australia reports on a genetic analysis of 394 patients who took part in a phase III study comparing the monoclonal antibody cetuximab with best supportive care.

The latest analysis compared the effect of mutations in the K-Ras gene on overall survival and progression-free survival. The gene encodes a protein that is a key component of cellular signalling pathways, conveying extracellular growth signals from the cell surface to the nucleus. When growth factors bind to cell surface receptors, including epidermal growth factor receptor (EGFR), K-Ras is temporarily activated, facilitating regulated cell growth and proliferation.

The K-Ras gene is mutated in up to 35% of colorectal cancers. These mutations keep K-Ras stuck in its active form, switching on signalling without the requirement for EGFR stimulation.

Dr. Karapetis and colleagues found that patients with mutated forms of K-Ras had a median overall survival of 4.6 months when treated with cetuximab, and 4.5 moths with supportive care. In contrast, among those with wild-type forms, overall survival jumped to 9.5 months when treated with cetuximab, compared to 4.8 months with best supportive care.

The results show that determining K-Ras mutation status should be considered a new standard of care for selecting patients for targeted therapies against EGFR, the authors say.

Also at the congress, Professor Eric Van Cutsem from University Hospital Gasthuisberg, Leuven in Belgium will present data on the impact of K-Ras mutations from the Crystal study, in which patients were randomized to either the chemotherapy combination "FOLFIRI" or FOLFIRI plus cetuximab, in first line metastatic colorectal cancer.

Professor Van Cutsem recently reported that the combination of cetuximab and FOLFIRI significantly improves progression free survival and response rate in patients with a K-Ras wild type. In Stockholm he will present new data on survival in the Crystal trial.

"Overall survival in all patients included in the trial was identical in both treatment arms. There was however a strong trend towards a longer survival in patients with a K-Ras wild type tumor treated with cetuximab/FOLFIRI," he said. The median survival was 24.9 months for patients who received the cetuximab combination, versus 21.0 months (HR: 0.84). The overall survival results in patients with K-Ras mutant tumors did not differ in the two study arms.

In another study, Dr. Miriam Koopman from the University Nijmegen Medical Centre St. Radboud in The Netherlands, reports that the number of tumor cells found circulating in the blood of patients with advanced colorectal cancer is another valuable predictor of survival.

Her group studied 467 patients who were being treated within a prospective clinical trial (CAIRO2 of the Dutch Colorectal Cancer Group) with chemotherapy plus bevacizumab, with or without the addition of cetuximab. In each patient they measured levels of circulating tumor cells before treatment, and at different stages during treatment.

"Circulating tumor cell (CTC) level might be an indicator of the aggressiveness of disease," Dr. Koopman explained. "Thus, a high CTC level before initiating therapy in metastatic colorectal cancer patients is an inferior prognostic factor in our study."

The results show that the median progression-free survival time for patients with less than three CTC in every 7.5mL of blood was 10.5 months, compared to 8.2 months for those with three or more. Furthermore the median overall survival time for patients with less than three CTC in every 7.5mL of blood was 22.2 months, compared to 13.7 months for those with three or more.

"In our study CTC in metastatic colorectal cancer patients proves to be an early prognostic marker," Dr. Koopman said. "Prospective trials are needed to investigate whether a change in therapy based on CTC is beneficial."


Story Source:

The above story is based on materials provided by European Society for Medical Oncology. Note: Materials may be edited for content and length.


Cite This Page:

European Society for Medical Oncology. "New Results Help Predict Treatment Response In Colorectal Cancer." ScienceDaily. ScienceDaily, 18 September 2008. <www.sciencedaily.com/releases/2008/09/080916101036.htm>.
European Society for Medical Oncology. (2008, September 18). New Results Help Predict Treatment Response In Colorectal Cancer. ScienceDaily. Retrieved November 24, 2014 from www.sciencedaily.com/releases/2008/09/080916101036.htm
European Society for Medical Oncology. "New Results Help Predict Treatment Response In Colorectal Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/09/080916101036.htm (accessed November 24, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, November 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Winter Can Cause Depression — Here's How To Combat It

Winter Can Cause Depression — Here's How To Combat It

Newsy (Nov. 23, 2014) Millions of American suffer from seasonal depression every year. It can lead to adverse health effects, but there are ways to ease symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins